F. Hirsch

发表

Role of Lactate in the Regulation of Transcriptional Activity of Breast Cancer-Related Genes and Epithelial-to-Mesenchymal Transition Proteins: A Compassion of MCF7 and MDA-MB-231 Cancer Cell Lines

F. Hirsch, C. Rivard, Hui Yu, 2023, bioRxiv.

Endobronchial miRNAs as Biomarkers in Lung Cancer Chemoprevention

William J Feser, York E Miller, Anna E Barón, 2012, Cancer Prevention Research.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Lawrence H. Schwartz, Donald A. Berry, Janis M. Taube, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

Paul Baas, Ignacio I. Wistuba, Robert Pirker, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Enzastaurin a protein kinase Cbeta-selective inhibitor, inhibits the growth of SCLC and NSCLC cell lines.

F. Hirsch, P. Bunn, D. Chan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.

G. Scagliotti, F. Hirsch, W. Franklin, 2003, Lung cancer.

A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

L. Schwartz, R. Herbst, F. Hirsch, 2020, Clinical lung cancer.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Robyn L. Temple-Smolkin, M. Ladanyi, Christina B. Ventura, 2018, The Journal of molecular diagnostics : JMD.

Robyn L. Temple-Smolkin, M. Ladanyi, Christina B. Ventura, 2018, Archives of pathology & laboratory medicine.

Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma

Steven J Frank, John V Heymach, Lucien Nedzi, 2016, Head & neck.

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.

F. Hirsch, K. Kerr, E. Van Cutsem, 2013, European journal of cancer.

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

Christine H Chung, Loris McGavran, Joel Parker, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer

F. Cappuzzo, F. Hirsch, P. Bunn, 2006, Clinical Cancer Research.

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

F. Hirsch, P. Bunn, D. Gandara, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung cancer: current therapies and new targeted treatments

Walter J Curran, James L Mulshine, W. Curran, 2017, The Lancet.

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

Chan Zeng, Anna E Barón, F. Hirsch, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of c-ErbB1/Epidermal Growth Factor Receptor and c-ErbB2/HER-2 Expression in Bronchial Dysplasia: Evaluation of Potential Targets for Chemoprevention of Lung Cancer

Y. Miller, F. Hirsch, W. Franklin, 2006, Clinical Cancer Research.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort

F. Hirsch, T. Mitsudomi, P. Bunn, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

F. Hirsch, C. Watkins, P. Bunn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

F. Cappuzzo, A. Gazdar, F. Hirsch, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Observation of a new particle in the search for the Standard Model Higgs boson with the ATLAS detector at the LHC

J. T. Childers, Chang Wei Loh, M. D. Pietra, 2012 .

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Paolo A Ascierto, Ariella Sasson, Ryan Golhar, 2018, Cancer cell.

The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

J. Austin, A. Nicholson, L. Chirieac, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genomic Testing in Lung Cancer: Past, Present, and Future.

F. Hirsch, M. Tsao, C. Mascaux, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

H. Ji, F. Hirsch, P. Bunn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Occurrence of neuron specific enolase in tumour tissue and serum in small cell lung cancer.

F. Hirsch, B. Skov, E. Cooper, 1991, British Journal of Cancer.

EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.

F. Hirsch, P. Bunn, W. Franklin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Expected Performance of the ATLAS Experiment - Detector, Trigger and Physics

M. L. Ferrer, J. T. Childers, Chang Wei Loh, 2008, 0901.0512.

Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis.

F. Hirsch, C. Powell, K. Fukunaga, 2021, Lung cancer.

Staging and prognostic factors in small cell lung cancer: a consensus report

R. Ginsberg, P. Houtte, F. Hirsch, 1989 .

Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels

Chan Zeng, Adi Gazdar, J. Minna, 2006, Clinical Cancer Research.

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.

A. Jimeno, F. Hirsch, W. Franklin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of Antitumor Response

F. Hirsch, Y. Shyr, F. Hirsch, 2011 .

Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment‐Naïve Lesions

F. Hirsch, T. Mitsudomi, Jihye Kim, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis

F. Hirsch, B. Skov, H. Nielsen, 1994, Histopathology.

The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis.

F. Hirsch, W. Franklin, R. Bremnes, 2002, Lung cancer.

Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective.

F. Hirsch, R. Dziadziuszko, F. Hirsch, 2008, Clinical lung cancer.

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

F. Hirsch, A. Armour, M. Varella‐Garcia, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

Elisa Rossi, Vienna Ludovini, Lucio Crino, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee

A. Nicholson, A. Borczuk, I. Wistuba, 2020, Journal of Thoracic Oncology.

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

Masahiro Tsuboi, Iver Petersen, Hisao Asamura, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Early detection of lung cancer by using an autoantibody panel in Chinese population

F. Hirsch, Hui Yu, H. Cai, 2018, Oncoimmunology.

Search for FCNC single top-quark production at √s = 7 TeV with the ATLAS detector

M. L. Ferrer, Alam, J. T. Childers, 2012, 1203.0529.

Lung cancer chemoprevention: moving from concept to a reality.

F. Hirsch, J. Mulshine, F. Hirsch, 2003, Lung cancer.

Lung cancer screening by spiral CT. What is the optimal target population for screening trials?

H. D. de Koning, R. V. van Klaveren, F. Hirsch, 2002, Lung cancer.

Search for Direct Top Squark Pair Production in Final States with One Isolated Lepton, Jets, and Missing Transverse Momentum in √s=7 TeV pp Collisions Using 4.7 fb[superscript -1] of ATLAS Data

J. T. Childers, Chang Wei Loh, H. S. Bansil, 2012 .

Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop

Michael Thomas, Federico Cappuzzo, Manfred Dietel, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Randomized Phase II Chemoprevention Trial of 13-CIS Retinoic Acid with Or without α Tocopherol or Observation in Subjects at High Risk for Lung Cancer

Y. Miller, F. Hirsch, K. Kelly, 2009, Cancer Prevention Research.

Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution

F. Hirsch, P. Bunn, Z. Lohinai, 2020, Molecular oncology.

Small Cell Lung Cancer Neuroendocrine Subtypes are Associated with Different Immune Microenvironment and Checkpoint Molecule Distribution

F. Hirsch, P. Bunn, Z. Lohinai, 2020, bioRxiv.

Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.

F. Hirsch, Heshui Shi, X. Dai, 2019, Clinical lung cancer.

Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.

Manuel Hidalgo, Aik Choon Tan, Jordy Coffa, 2008, Cancer research.

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

G. Hampton, P. Hegde, I. Wistuba, 2018, Proceedings of the National Academy of Sciences.

EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis.

F. Hirsch, C. Rivard, Hui Yu, 2019, Cancer treatment reviews.

Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

C. Henschke, J. Minna, F. Hirsch, 2021, Journal of Thoracic Oncology.

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins

A. Jimeno, F. Hirsch, M. Varella‐Garcia, 2013, Molecular oncology.

Search for displaced vertices arising from decays of new heavy particles in 7 TeV pp collisions at ATLAS

M. L. Ferrer, J. T. Childers, Chang Wei Loh, 2011, 1109.2242.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe

Carsten Denkert, Fred Hirsch, Benjamin Solomon, 2017, Advances in anatomic pathology.

Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation

F. Hirsch, T. Mitsudomi, Jihye Kim, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Non-invasive Breath Analysis of Pulmonary Nodules

H. Haick, Y. Miller, F. Hirsch, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.

Charles A Powell, Elisabeth Brambilla, Kavita Garg, 2011, Proceedings of the American Thoracic Society.

Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers

Y. Miller, J. Minna, P. Massion, 2011, Cancer Prevention Research.

PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project

F. Hirsch, K. Kerr, M. Tsao, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Elisa Rossi, Vienna Ludovini, Lucio Crino, 2005, Journal of the National Cancer Institute.

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

F. Hirsch, P. Bunn, H. Popper, 2023, CA: a cancer journal for clinicians.

Clinical potential of necitumumab in non-small cell lung carcinoma

F. Hirsch, C. Genova, F. Hirsch, 2016, OncoTargets and therapy.

Galectin-9 in non-small cell lung cancer.

F. Hirsch, R. Dziadziuszko, Xiaoshen Zhang, 2019, Lung Cancer.

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

R. Gray, R. Caprioli, P. Massion, 2007, Journal of the National Cancer Institute.

Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort.

J. Herman, S. Baylin, T. Byers, 2006, Cancer research.

Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer

F. Hirsch, Z. Lohinai, C. Rivard, 2022, Cancer Immunology, Immunotherapy.

Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer

F. Hirsch, Z. Lohinai, C. Rivard, 2021, Biology.

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

I. Wistuba, F. Hirsch, D. Rimm, 2021, Nature Reviews Clinical Oncology.

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America

I. Wistuba, F. Hirsch, C. Vallejos, 2017, Clinical lung cancer.

Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.

E. Gabrielson, F. Hirsch, P. Bunn, 2002, Cancer research.

Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics

P. Hammerman, F. Hirsch, D. Gandara, 2015, Clinical Cancer Research.

Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.

Simion I. Chiosea, G. Mills, A. Jimeno, 2017, JCI insight.

Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.

F. Cappuzzo, F. Hirsch, T. Boggon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer.

E. Gabrielson, F. Hirsch, W. Franklin, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

F. Hirsch, P. Bunn, R. Dziadziuszko, 2014, Clinical Cancer Research.

A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines

F. Hirsch, D. Gao, C. Rivard, 2018, Clinical lung cancer.

Clinicopathologic Features of Advanced Squamous NSCLC.

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

G. Giaccone, M. Krasnow, C. Rudin, 2022 .

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer

F. Hirsch, M. Varella‐Garcia, R. Dziadziuszko, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers

A. Jimeno, F. Bootz, F. Hirsch, 2015, Clinical Cancer Research.

Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib

Derek E. Smith, F. Hirsch, D. Gao, 2019, Clinical lung cancer.

Strategies in Patients with Other Molecular Alterations

F. Hirsch, M. D'Arcangelo, F. Hirsch, 2015 .

Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer

F. Hirsch, R. Dziadziuszko, J. Jassem, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Increased Insulin-Like Growth Factor 1 Receptor Protein Expression and Gene Copy Number in Small Cell Lung Cancer

F. Hirsch, R. Dziadziuszko, F. Gaire, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer

F. Cappuzzo, F. Hirsch, M. Varella-Garcia, 2009, Oncogene.

Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.

F. Cappuzzo, F. Hirsch, P. Bunn, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Insulin-like growth factor receptor 1 (IGFR-1) is signiﬁcantly associated with longer survival in non-small-cell lung cancer patients treated with geﬁtinib

F. Hirsch, P. Bunn, W. Franklin, 2006 .

Assessing the association of diabetes with lung cancer risk

A. Leiter, F. Hirsch, D. Leroith, 2021, Translational lung cancer research.

Chemoprevention of lung cancer: current status and future prospects.

F. Hirsch, N. van Zandwijk, F. Hirsch, 2003, Lung cancer.

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Clare C. Yu, M. N. Vidya, 2021, npj Breast Cancer.

Benjamin Solomon, Neal I. Lindeman, Dara L. Aisner, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The International Association for the Study of Lung Cancer Early Lung Imaging Confederation

P. V. van Ooijen, M. Oudkerk, S. Lam, 2020, JCO clinical cancer informatics.

Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications

William Pao, Erika Avila-Tang, J. Herman, 2009, Clinical Cancer Research.

Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma.

F. Hirsch, B. Skov, H. Hansen, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer

Wei Zhang, Soma Das, F. Hirsch, 2011, Clinical Cancer Research.

Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status

F. Hirsch, T. Mitsudomi, C. Rivard, 2017, PloS one.

The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients.

I. Wistuba, F. Hirsch, Z. Cooper, 2021, Clinical lung cancer.

PACIFIC trial: new perspectives for immunotherapy in lung cancer.

F. Hirsch, F. Agustoni, F. Hirsch, 2018, Translational lung cancer research.

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee

A. Nicholson, A. Borczuk, I. Wistuba, 2020 .

PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee.

N. Girard, A. Nicholson, A. Borczuk, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PD‐L1 Immunohistochemistry Comparability Study in Real‐Life Clinical Samples: Results of Blueprint Phase 2 Project

Hui Yu, Keith M. Kerr, Ignacio Wistuba, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation

K. Rosenzweig, M. Zauderer, V. Rusch, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

F. Hirsch, A. Tsao, L. Mutti, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Consensus Report of the 2015 Weinman International Conference on Mesothelioma

J. Peto, W. Mao, F. Hirsch, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations

T. Ohira, M. Tsuboi, Koichi Yoshida, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR testing in lung cancer is ready for prime time.

F. Hirsch, P. Bunn, Fred R Hirsch, 2009, The Lancet. Oncology.

Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.

F. Hirsch, T. Mitsudomi, K. Politi, 2017, Lung cancer.

PD‐L1 Expression in Lung Cancer

F. Hirsch, D. Rimm, Hui Yu, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of Real‐World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death‐1 and Programmed Cell Death‐Ligand 1 Inhibitors in Advanced Non‐Small Cell Lung Cancers

E. Schadt, W. Oh, F. Hirsch, 2021, The oncologist.

NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort

F. Hirsch, S. Heynemann, Hongfeng Yu, 2021, Clinical Lung Cancer.

The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer.

Edward S. Kim, M. Tsuboi, G. Scagliotti, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer

S. Knapp, F. Hirsch, C. Mascaux, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Comprehensive Immune Profiling of Medullary Thyroid Cancer.

F. Hirsch, B. Haugen, C. Rivard, 2020, Thyroid : official journal of the American Thyroid Association.

Comprehensive Immune Proﬁling of Medullary Thyroid Cancer

F. Hirsch, B. Haugen, C. Rivard, 2020 .

LAG‐3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD‐1/PD‐L1 and Tumor‐Infiltrating Lymphocytes

F. Hirsch, R. Dziadziuszko, C. Rivard, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse

F. Hirsch, R. Dziadziuszko, Jie Chen, 2021, Translational lung cancer research.

The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review

F. Hirsch, Caicun Zhou, Yayi He, 2021, Translational lung cancer research.

T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer.

F. Hirsch, R. Dziadziuszko, Hui Yu, 2019, Translational lung cancer research.

Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer?

F. Hirsch, R. Dziadziuszko, Xiaoshen Zhang, 2019, Translational lung cancer research.

OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.

F. Hirsch, R. Dziadziuszko, Xiaoshen Zhang, 2019, Translational lung cancer research.

sLAG-3 in non-small-cell lung cancer patients’ serum

F. Hirsch, Caicun Zhou, Chao Zhao, 2018, OncoTargets and therapy.

Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer

F. Hirsch, C. Rivard, Hui Yu, 2016, Cancer science.

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma

F. Hirsch, C. Rivard, D. Chan, 2016, Medical science monitor : international medical journal of experimental and clinical research.

βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer

M. Engelhard, F. Hirsch, T. Gauler, 2012, British Journal of Cancer.

EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.

S. Armato, P. Courtiol, N. Girard, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

R. Govindan, F. Hirsch, M. Brown, 2014, Clinical cancer research : an official journal of the American Association for Cancer Research.

Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.

F. Hirsch, P. Bunn, W. Franklin, 2002, Clinical breast cancer.

Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.

F. Hirsch, P. Bunn, W. Franklin, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark.

J. Olsen, F. Hirsch, H. Hansen, 2002, Lung cancer.

EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.

F. Hirsch, Jing Zhao, T. Jiang, 2018, Lung cancer.

2006 Highlights From: The Third International Association for the Study of Lung Cancer/American Society of Clinical Oncology/European Society of Medical Oncology International Conference on Molecular-Targeted Therapies in Lung Cancer Taormina, Sicily; November 2006

R. Herbst, F. Hirsch, H. Pass, 2007 .

Tumor Mutation Burden: Promises and Challenges A Perspective from the IASLC Pathology Committee.

A. Nicholson, A. Borczuk, I. Wistuba, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Akihiko Yoshida, Mari Mino-Kenudson, Arne Warth, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PL 03.03 Blueprint 2: PD-L1 Immunohistochemistry Comparability Study in Real-Life, Clinical Samples

Keith M. Kerr, F. Hirsch, Y. Yatabe, 2017 .

Baseline extracellular vesicle TGF‐β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non–small cell lung cancer

F. Hirsch, V. Adamo, A. Naing, 2022, Cancer.

PD‐L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer

F. Hirsch, R. Dziadziuszko, D. Gao, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Scientific Advances in Lung Cancer 2015

Kenneth E. Rosenzweig, Hisao Asamura, Annette McWilliams, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Correlation of PD‐L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early‐Stage Squamous Cell Lung Carcinoma

D. Beer, Guoan Chen, L. Chirieac, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung Cancer

F. Hirsch, P. Bunn, D. Gandara, 2010, Clinical Cancer Research.

TIM-3, a promising target for cancer immunotherapy

F. Hirsch, Caicun Zhou, Xue-Fei Li, 2018, OncoTargets and therapy.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

L. Schwartz, R. Govindan, J. Neal, 2022, Journal for ImmunoTherapy of Cancer.

Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non–Small Cell Lung Cancer

F. Hirsch, D. Doroshow, S. Bhalla, 2020, Cancer journal.

HER2/neu expression in malignant lung tumors.

F. Hirsch, P. Bunn, W. Franklin, 2002, Seminars in oncology.

A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers

E. Schadt, F. Hirsch, Rong Chen, 2021, BMC cancer.

Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?

F. Hirsch, P. Mack, C. Rolfo, 2023, Clinical lung cancer.

The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers.

Fred Hirsch, Wilbur Franklin, Frank Cuttitta, 2008, The Journal of clinical investigation.

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

R. Herbst, F. Hirsch, K. Kelly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Biology of Epidermal Growth Factor Receptor in Lung Cancer

G. Scagliotti, F. Hirsch, S. Novello, 2004, Clinical Cancer Research.

Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2006, Clinical Cancer Research.

Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer

F. Hirsch, Fred R Hirsch, Samir Witta, 2005, Current opinion in oncology.

Epidermal growth factor receptor family in lung cancer and premalignancy.

F. Hirsch, P. Bunn, W. Franklin, 2002, Seminars in oncology.

Pathologic considerations and standardization in mesothelioma clinical trials.

A. Nicholson, F. Galateau-Sallé, D. Gomez, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

J. Szustakowski, P. Ascierto, F. Hirsch, 2019, Cancer cell.

The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations

F. Aboitiz, F. Hirsch, D. Gandara, 2022, JCO global oncology.

Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical T

S. Armato, E. Yorke, K. Rosenzweig, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

J. Taube, I. Wistuba, F. Hirsch, 2017, JAMA oncology.

Early detection and screening of lung cancer

F. Hirsch, C. Mascaux, M. Wynes, 2010, Expert review of molecular diagnostics.

Recent developments in biomarkers for the early detection of lung cancer: perspectives based on publications 2003 to present

F. Hirsch, W. Franklin, D. Merrick, 2004, Current opinion in pulmonary medicine.

From Expert Review of Molecular Diagnostics

F. Hirsch, C. Mascaux, M. Wynes, 2010 .

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

J. Minna, L. Girard, A. Gazdar, 2006, Cancer research.

Neuroendocrine characteristics in bronchogenic adenocarcinoma and its clinical relevance

F. Hirsch, B. Skov, F. Hirsch, 1993 .

Neuroendocrine characteristics in malignant lung tumors: implications for diagnosis, treatment, and prognosis.

F. Hirsch, B. Skov, T. Senderovitz, 1995, Cancer treatment and research.

Molecular and Cell Biology of Lung Carcinoma

F. Hirsch, W. Franklin, F. Hirsch, 2004 .

Targeting Anemia in Patients with Lung Cancer

F. Hirsch, J. Crawford, C. Langer, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay

F. Hirsch, D. Gandara, J. Moon, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.

F. Hirsch, J. Hornberger, R. Page, 2015, Lung cancer.

Quality of care of patients with non-small-cell lung cancer: a report of a performance improvement initiative.

F. Hirsch, C. Berry, R. Jotte, 2014, Cancer control : journal of the Moffitt Cancer Center.

From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers

J. Minna, A. Gazdar, F. Hirsch, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The impact of abdominal computerized tomography on the pretreatment staging and prognosis of small cell lung cancer.

F. Hirsch, H. Hansen, C. Thomsen, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Original article: Combination chemotheraphy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens

F. Hirsch, H. Hansen, P. Dombernowsky, 1991 .

The presence of circulating genetically abnormal cells in blood predicts risk of lung cancer in individuals with indeterminate pulmonary nodules

C. Henschke, D. Yankelevitz, F. Hirsch, 2023, BMC Pulmonary Medicine.

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy

Chao Li, Gang Han, Marius Ilie, 2019, Modern Pathology.

Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up.

F. Hirsch, H. Hansen, P. Kristjansen, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

V. Torri, N. Reinmuth, H. Wakelee, 2022, Journal of Thoracic Oncology.

ROS1 Immunohistochemistry Among Major Genotypes of Non—Small-Cell Lung Cancer

F. Hirsch, Y. Yatabe, T. Boyle, 2014, Clinical lung cancer.

Tumorigenesis and Neoplastic Progression Analysis of Orthologous Gene Expression between Human Pulmonary Adenocarcinoma and a Carcinogen-Induced Murine Model

Raphael A Nemenoff, L. Dwyer-Nield, A. Malkinson, 2010 .

Radiotherapy and Immunotherapy in Lung Cancer

K. Rosenzweig, F. Hirsch, R. Samstein, 2023, Biomedicines.

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators

M. Dietel, F. Hirsch, E. Schuuring, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer

F. Hirsch, M. Wynes, M. D'Arcangelo, 2013, Current opinion in oncology.

Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

F. Hirsch, D. Lipson, P. Bunn, 2015, The oncologist.

Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.

M. Lucia, A. Jimeno, A. Thorburn, 2013, Cancer research.

Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma.

A. Nicholson, D. Yankelevitz, I. Wistuba, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

L. Schwartz, R. Govindan, J. Neal, 2018, Journal of Immunotherapy for Cancer.

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

F. Hirsch, R. Dziadziuszko, C. Rivard, 2017, Medical science monitor : international medical journal of experimental and clinical research.

Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?

Ming-Sound Tsao, Ignacio I Wistuba, A. Nicholson, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

J. Austin, I. Petersen, V. Rusch, 2011, Journal of Thoracic Oncology.

Chemoprevention strategies for non-small cell lung cancer

F. Hirsch, N. van Zandwijk, F. Hirsch, 2002, Current opinion in oncology.

Analysis of c-ErbB1/Epidermal Growth Factor Receptor and c-ErbB2/HER-2 Expression in Bronchial Dysplasia: Evaluation of Potential Targets for Chemoprevention of Lung Cancer

Y. Miller, W. Franklin, R. Winterhalder, 2006, Clinical Cancer Research.

Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

David Wholley, Jeffrey D Bradley, Dana Sparks, 2015, Clinical Cancer Research.

Molecular Biomarkers Workshop: a European Strategy for Developing Lung Cancer Molecular Diagnostics in High Risk Populations

F. Hirsch, J. Mulshine, T. Sutedja, 2001 .

Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations

T. Ohira, M. Tsuboi, Koichi Yoshida, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

C. Watkins, P. Bunn, W. Franklin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and comparative utility of afatinib in non-small cell lung cancer

F. Hirsch, M. D'Arcangelo, F. Hirsch, 2014, Biologics : targets & therapy.

Epidermal growth factor receptor inhibition in lung cancer: status 2012.

Edward S. Kim, P. Jänne, F. Cappuzzo, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A new generation of EGFR tyrosine-kinase inhibitors in NSCLC.

P. Bunn, F. Hirsch, 2012, The Lancet. Oncology.

Clinical and comparative utility of afatinib in non-small cell lung cancer

M. D'Arcangelo, F. Hirsch, 2014 .

Clinical and comparative utility of afatinib in non-small cell lung cancer

M. D'Arcangelo, F. Hirsch, 2014 .

Clinical and comparative utility of afatinib in non-small cell lung cancer

M. D'Arcangelo, F. Hirsch, 2014 .

Clinical and comparative utility of afatinib in non-small cell lung cancer

M. D'Arcangelo, F. Hirsch, 2014 .

Epidermal Growth Factor Receptor Inhibition in Lung Cancer

Edward S. Kim, P. Jänne, F. Cappuzzo, 2013 .

Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases.

F. Hirsch, Z. Lohinai, J. Moldvay, 2019, Translational lung cancer research.

RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer

K. Edlund, F. Hirsch, H. Popper, 2017, Genes & development.

IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY.

Prasad Adusumilli, Young Tae Kim, Ugo Pastorino, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

D. Yankelevitz, I. Wistuba, R. Herbst, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer

S. Serrano, M. Salido, F. Hirsch, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).

F. Hirsch, P. Bunn, R. Dziadziuszko, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A Grading system for invasive pulmonary adenocarcinoma: a proposal from the IASLC pathology committee.

A. Nicholson, A. Borczuk, I. Wistuba, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Epidermal Growth Factor Receptor Targeted Therapy—Markers of Sensitivity and Response

F. Hirsch, R. Dziadziuszko, B. Szostakiewicz, 2016 .

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer

T. Ohira, Koichi Yoshida, N. Ikeda, 2013, Cellular Oncology.

Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819

J. Crowley, R. Herbst, F. Hirsch, 2012, Clinical Cancer Research.

EGFR Protein Expression in Non–Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor—A Novel Antibody for Immunohistochemistry or AQUA Technology

Cindy Tran, Toshitaka Nagao, Norihiko Ikeda, 2011, Clinical Cancer Research.

Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Review: Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer

Koichi Yoshida, F. Hirsch, M. Wynes, 2009, Therapeutic advances in medical oncology.

Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib

Marie C. South, F. Hirsch, P. Bunn, 2009, Clinical and translational science.

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status.

F. Hirsch, E. Duffield, A. Armour, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2008, Clinical Cancer Research.

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.

F. Cappuzzo, F. Hirsch, E. Duffield, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2

J. Crowley, F. Hirsch, A. Wozniak, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay.

F. Hirsch, P. Bunn, D. Gandara, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Epidermal growth factor receptor immunohistochemistry

F. Hirsch, C. Watkins, P. Bunn, 2008, Cancer.

EGFR Inhibitors in the Treatment of Lung Cancer

F. Hirsch, F. Hirsch, 2007, Oncology Research and Treatment.

M03-04: Selecting lung cancer patients to targeted therapies based on protein expression by immunohistochemistry

F. Hirsch, R. Dziadziuszko, F. Hirsch, 2007 .

EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

F. Cappuzzo, F. Hirsch, M. Varella‐Garcia, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies.

F. Hirsch, D. Gandara, P. Mack, 2007, Clinical lung cancer.

Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy.

F. Hirsch, P. Bunn, W. Franklin, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of EGFR family in preneoplasia and lung cancer; Perspectives for targeted therapies and selection of patients

F. Hirsch, F. Hirsch, 2006 .

Fluorescence In situ Hybridization Subgroup Analysis ofTRIBUTE , a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non ^ Small Cell Lung Cancer

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2008 .

O-107 FISH and Immunohistochemistry (IHC) can be used to selectNSCLC patients, who will not benefit from gefitinib treatment

F. Hirsch, P. Bunn, D. Gandara, 2005 .

New and emerging targeted treatments in advanced non-small-cell lung cancer

F. Hirsch, P. Bunn, Jacinta R. Wiens, 2016, The Lancet.

Clinician Perspectives on Current Issues in Lung Cancer Drug Development

P. Jänne, R. Govindan, R. Herbst, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter.

F. Hirsch, T. Mitsudomi, C. Rivard, 2016, Cancer research.

Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials.

F. Hirsch, D. Gandara, M. Redman, 2016, JAMA oncology.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

C. Schumann, M. Socinski, R. Kurek, 2015, The Lancet. Oncology.

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.

Edward S. Kim, C. Obasaju, M. Socinski, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non–Small-Cell Lung Cancer

Paul Delmar, F. Hirsch, F. Shepherd, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR tyrosine kinase inhibitors in squamous cell lung cancer.

R. Herbst, F. Hirsch, D. Gandara, 2015, The Lancet. Oncology.

EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324.

W. Curran, H. Choy, F. Hirsch, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.

F. Cappuzzo, C. Gridelli, F. Hirsch, 2014, Clinical lung cancer.

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.

F. Hirsch, P. Bunn, W. Franklin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms

F. Hirsch, T. Mitsudomi, C. Rivard, 2017, Expert review of anticancer therapy.

Long‐term safety and survival with gefitinib in select patients with advanced non–small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)

L. Sequist, F. Hirsch, P. Bunn, 2018, Cancer.

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Three‐arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non–small cell lung cancer (NSCLC) patients who will not receive bevacizumab‐based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)

N. Hanna, F. Hirsch, S. Ramalingam, 2012, Cancer.

Primary Double‐Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench

F. Hirsch, T. Mitsudomi, P. Bunn, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The role of HER2/neu expression and trastuzumab in non-small cell lung cancer.

F. Hirsch, C. Langer, F. Hirsch, 2004, Seminars in oncology.

Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed

T. Gauler, M. Schuler, M. Wynes, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

M. Socinski, R. Kurek, F. Hirsch, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

P. Bunn, R. Dziadziuszko, D. Gao, 2014, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFRTKI Sensitivity across All LungCancer Histologies

F. Hirsch, P. Bunn, R. Dziadziuszko, 2014 .

Lung Cancer Prevention

F. Hirsch, N. Peled, R. Keith, 2010 .

Advances in the biology of lung cancer chemoprevention.

S. Lippman, F. Hirsch, F. Hirsch, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoprevention of lung cancer--from biology to clinical reality.

F. Hirsch, P. Bunn, W. Franklin, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Scientific Advances in Thoracic Oncology 2016.

H. Groen, C. Rudin, R. Rami-Porta, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

F. Hirsch, P. Bunn, W. Franklin, 2002, British Journal of Cancer.

Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?

F. Hirsch, P. Bunn, F. Hirsch, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients.

F. Hirsch, T. Gauler, M. Schuler, 2014, Clinical lung cancer.

Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed.

F. Hirsch, T. Gauler, M. Schuler, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.

F. Hirsch, M. Varella‐Garcia, D. Aisner, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.

F. Hirsch, J. Ahn, M. Ahn, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.

I. Wistuba, F. Hirsch, S. Ou, 2015, The oncologist.

Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of “Master Protocols” in Lung Cancer

Richard Pazdur, Edward L. Korn, Jeffrey S. Abrams, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type

F. Hirsch, S. Ren, Caicun Zhou, 2014, Oncotarget.

The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer

F. Hirsch, S. Ren, Caicun Zhou, 2014, Cancer.

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer

F. Hirsch, W. Franklin, M. Varella‐Garcia, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Biomarkers are here to stay for clinical research and standard care.

F. Hirsch, P. Bunn, W. Franklin, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecularly targeted therapy: when to stop and when to continue?

F. Hirsch, T. Mok, P. Bunn, 2010, The Lancet. Oncology.

The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC

F. Hirsch, F. Hirsch, 2009, Oncogene.

Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non–Small‐cell Lung Cancer: SWOG S0635 and S0636 Trials

F. Hirsch, K. Kelly, A. Wozniak, 2018, Clinical lung cancer.

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Susanne M Arnold, Mary W Redman, Karen Kelly, 2018, The Lancet. Oncology.

Volatile fingerprints of cancer specific genetic mutations.

Radu Ionescu, Ulrike Tisch, Hossam Haick, 2013, Nanomedicine : nanotechnology, biology, and medicine.

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer

F. Hirsch, R. Dziadziuszko, J. Jassem, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

7.1.1 Invited: Chemical Nanoarrays for Early Detection and Screening of Lung Cancer via Volatile Biomarkers

H. Haick, Y. Miller, F. Hirsch, 2012 .

The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review

Anna Spreafico, Mauro Papotti, F. Hirsch, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment

F. Hirsch, I. Vergote, T. Macarulla, 2023, Cancers.

A Proposed System Toward Standardizing Surgery-based Treatments for Malignant Pleural Mesothelioma, From the Joint NCI-IASLC-MARF Taskforce.

D. Sugarbaker, F. Hirsch, H. Pass, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

E. Yorke, K. Rosenzweig, V. Rusch, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma

F. Hirsch, T. Gauler, M. Schuler, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines

Chan Zeng, F. Hirsch, P. Bunn, 2006, Molecular Cancer Research.

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

F. Cappuzzo, F. Hirsch, P. Bunn, 2005, British Journal of Cancer.

AntitumorActivityof the EpidermalGrowth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non^Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFRMutations but not EGFRProtein Levels

A. Gazdar, F. Hirsch, P. Bunn, 2006 .

Evaluation of HER2/neu expression in lung tumors by immunohistochemistry and fluorescence in situ hybridization (FISH)

F. Hirsch, P. Bunn, W. Franklin, 2000 .

Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology.

A. Gazdar, F. Hirsch, P. Bunn, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives.

K. Rosenzweig, F. Hirsch, C. Powell, 2020, Lung cancer.

IASLC Global Survey on PD-L1 Testing for Non-Small Cell Lung Cancer.

N. Le Stang, A. Nicholson, A. Borczuk, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases

F. Hirsch, W. Franklin, M. Wislez, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Detection of Chromosomal Aneusomy by Fluorescence In situ Hybridization in Sputum Predicts Lung Cancer Incidence

T. Byers, Y. Miller, F. Hirsch, 2010, Cancer Prevention Research.

Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development

C. Korch, S. Leong, J. Tentler, 2010, Clinical Cancer Research.

Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

P. Stephens, M. Cronin, F. Hirsch, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Contributions of KRAS and RAL in Non–Small-Cell Lung Cancer Growth and Progression

F. Hirsch, D. Theodorescu, M. Wynes, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal.

F. Hirsch, P. Bunn, D. Gandara, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.

Edward S. Kim, J. Crowley, R. Herbst, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Observation of a new particle in the search for the Standard Model Higgs boson with the ATLAS detector at the LHC

J. T. Childers, Chang Wei Loh, H. S. Bansil, 2012 .

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536

Edward S. Kim, R. Herbst, F. Hirsch, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

c-MET as a biomarker in patients with surgically resected non-small cell lung cancer.

F. Hirsch, C. Rivard, S. Ekman, 2019, Lung cancer.

MHC class II expression in lung cancer.

F. Hirsch, R. Dziadziuszko, C. Rivard, 2017, Lung cancer.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

J. Szustakowski, P. Ascierto, Han Chang, 2018, Cancer cell.

EGFR‐TKIs plus local therapy demonstrated survival benefit than EGFR‐TKIs alone in EGFR‐mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases

F. Hirsch, J. Zhao, Qinghua Xu, 2018, International journal of cancer.

Comprehensive Analysis of EGFR‐Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations

F. Hirsch, Guohua Yang, S. Ren, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.

D. Lin, F. Hirsch, S. Chuai, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer

Ningning Cheng, Jiayu Li, Ke Fei, 2015, Oncotarget.

Long non-coding RNA UCA 1 induces non-T 790 M acquired resistance to EGFR-TKIs by activating the AKT / mTOR pathway in EGFR-mutant non-small cell lung cancer

F. Hirsch, Xiaoxiang Chen, S. Ren, 2015 .

Heterogeneity of PD‐L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma

Tao Jiang, Wei Zhang, F. Hirsch, 2018, Clinical lung cancer.

Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors.

F. Cappuzzo, R. Herbst, T. Mitsudomi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.

F. Hirsch, D. Gao, C. Rivard, 2018, Lung cancer.

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee.

I. Wistuba, M. Mino‐Kenudson, F. Hirsch, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer

F. Hirsch, T. Jiang, S. Ren, 2020, Journal of Cancer.

Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies

Ahnalee M. Brincks, J. M. Crawford, Stefani N. Thomas, 2022, Open forum infectious diseases.

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases

F. Hirsch, C. Rivard, S. Ren, 2016, OncoTargets and therapy.

Clinical potential of necitumumab in non-small cell lung carcinoma

C. Genova, F. Hirsch, 2016, OncoTargets and therapy.

Consensus for HER2 alterations testing in non-small-cell lung cancer

F. Hirsch, T. Mitsudomi, X. Wang, 2022, ESMO open.

Lung Cancer Fluorescence In Situ Hybridization , Immunohistochemistry , and Next-Generation Sequencing for Detection of EML 4-ALK Rearrangement in Lung Cancer

F. Hirsch, D. Lipson, P. Bunn, 2015 .

Targeting BRAF mutations in non-small cell lung cancer.

F. Hirsch, N. Pavlakis, K. O'Byrne, 2019, Translational lung cancer research.

CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancer.

F. Hirsch, Z. Lohinai, T. Jiang, 2021, Lung cancer.

Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC

F. Hirsch, Hui Yu, Jing Zhao, 2017, Theranostics.

Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules

F. Hirsch, C. Rivard, S. Ren, 2017, OncoTargets and therapy.

Risk factors for nicotine dependence in Chinese patients with lung cancer

F. Hirsch, Caicun Zhou, Xue-Fei Li, 2018, The Journal of international medical research.

Serum microRNAs improving the diagnostic accuracy in lung cancer presenting with pulmonary nodules.

F. Hirsch, S. Ren, Caicun Zhou, 2018, Journal of thoracic disease.

Independent validation test of the vote-counting strategy used to rank biomarkers from published studies.

F. Hirsch, A. Baron, M. Wynes, 2015, Biomarkers in medicine.

Treatment of spine metastases in cancer: a review

F. Hirsch, Caicun Zhou, Xue-Fei Li, 2019, Journal of International Medical Research.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

C. Schumann, M. Socinski, R. Kurek, 2015, The Lancet. Oncology.

Real‐World longitudinal practice patterns in the use of PD‐1 and PD‐L1 inhibitors as First‐Line therapy in patients with Non‐Small cell lung cancer in the United States

F. Hirsch, E. Taioli, J. Wisnivesky, 2022, Cancer medicine.

Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer

F. Hirsch, Mengting Zhou, Zhenyu Li, 2019, Respiratory Research.

Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy

F. Hirsch, A. Allen, T. Siegal, 2016, Journal of Clinical Neuroscience.

Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Clinical lung cancer.

Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction.

T. Byers, Y. Miller, F. Hirsch, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers

Y. Miller, J. Minna, P. Massion, 2011, Cancer Prevention Research.

Intracranial metastases in small cell carcinoma of the lung prognostic aspects

F. Hirsch, H. Hansen, O. Paulson, 1983, Cancer.

Staging procedures in small cell lung cancer

F. Hirsch, F. Hirsch, 1989 .

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

H. V. van Houwelingen, F. Hirsch, J. Neijt, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KRAS G12C-mutant non-small-cell lung cancer: biology, developmental therapeutics, and molecular testing.

F. Hirsch, P. Mack, J. Houldsworth, 2021, The Journal of molecular diagnostics : JMD.

Measurement of the inclusive W± and Z/γ* cross sections in the e and μ decay channels in pp collisions at √s = 7 TeV with the ATLAS detector

M. L. Ferrer, J. T. Childers, Chang Wei Loh, 2012 .

Searches for heavy long-lived sleptons and R-hadrons with the ATLAS detector in pp collisions at √s=7 TeV

J. T. Childers, Chang Wei Loh, M. D. Pietra, 2013 .

A Particle Consistent with the Higgs Boson Observed with the ATLAS Detector at the Large Hadron Collider

J. T. Childers, Chang Wei Loh, M. D. Pietra, 2012, Science.

Title : Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer

M. Lucia, A. Jimeno, A. Thorburn, 2013 .

Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis.

F. Hirsch, H. Hansen, I. Christensen, 1980, Cancer research.

Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization.

Y. Miller, F. Hirsch, L. Morrison, 2003, The Journal of molecular diagnostics : JMD.

Physician Bias in Prophylactic Cranial Irradiation Decision Making—An Opportunity for a Patient Decision Aid

F. Hirsch, L. Gaspar, F. Kong, 2018, Clinical lung cancer.

cMET Exon 14 Skipping: From the Structure to the Clinic.

E. Giovannetti, G. Peters, F. Cappuzzo, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

1330TiPA PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER TRIAL OF DENOSUMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER.

G. Weiss, D. Spigel, J. Crawford, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Future developments in the treatment of lung cancer.

F. Hirsch, J. Nikliński, J. Fischer, 2002, Lung cancer.

Expression of target molecules in lung cancer: challenge for a new treatment paradigm.

F. Hirsch, P. Bunn, W. Franklin, 2002, Seminars in oncology.

Should maintenance chemotherapy be used to treat small cell lung cancer?

F. Hirsch, H. Hansen, J. Sculier, 1998, European journal of cancer.

Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress?

F. Hirsch, P. Dombernowsky, B. Bergman, 1997, Lung cancer.

The mTOR pathway in lung cancer and implications for therapy and biomarker analysis.

F. Hirsch, M. Wynes, S. Ekman, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria

A. Nicholson, D. Yankelevitz, I. Wistuba, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Incidence of lung cancer in Denmark: historical and actual status.

J. Olsen, F. Hirsch, H. Skuladottir, 1999, Lung cancer.

Metastatic patterns in small-cell lung cancer: correlation of autopsy findings with clinical parameters in 537 patients.

F. Hirsch, H. Hansen, J. Elliott, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression differences in current versus former smokers lung squamous preneoplasia.

Benjamin Haibe-Kains, A. Burny, V. Ninane, 2010 .

Spectral karyotyping detects chromosome damage in bronchial cells of smokers and patients with cancer.

Y. Miller, F. Hirsch, W. Franklin, 2007, American journal of respiratory and critical care medicine.

Corrigendum to 'Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer': [ESMO Open Volume 7 Issue 1 (2022) 100395].

T. Mitsudomi, J. Ying, Y. Shu, 2022, ESMO open.

IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001.

E. Dmitrovsky, C. Henschke, F. Hirsch, 2002, Lung cancer.

Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination.

F. Hirsch, H. Hansen, P. Dombernowsky, 1978, Annals of internal medicine.

An immunohistochemical investigation of diagnostic biopsy material taken from short and long term survivors with small cell lung cancer.

L. Happerfield, L. Bobrow, R. Souhami, 1992, British Journal of Cancer.

The clinical relevance of recent developments in pathology and biology of small cell lung cancer.

F. Hirsch, H. Hansen, F. Hirsch, 1989, Chest.

Immunoperoxidase staining for carcinoembryonic antigen in small cell carcinoma of the lung.

F. Hirsch, M. Sehested, K. Hou‐Jensen, 1981, European journal of cancer & clinical oncology.

BILATERAL BONE‐MARROW EXAMINATIONS IN SMALL‐CELL ANAPLASTIC CARCINOMA OF THE LUNG

F. Hirsch, H. Hansen, B. Hainau, 1979, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

Neonatal cancer in Denmark 1943-1985.

J. Olsen, F. Hirsch, K. Borch, 1994, Pediatric hematology and oncology.

Treatment of small-cell carcinoma of the lung monitored by sequential flow cytometric DNA analysis.

F. Hirsch, H. Hansen, N. Nissen, 1982, Cancer research.

National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers.

C. Gatsonis, D. Aberle, J. Minna, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Hormonal polypeptides and amine metabolites in small cell carcinoma of the lung, with special reference to stage and subtypes

J. M. Christensen, F. Hirsch, H. Hansen, 1980, Cancer.

UvA-DARE ( Digital Academic Repository ) Observation of a new particle in the search for the Standard Model Higgs boson with the ATLAS detector

J. T. Childers, Chang Wei Loh, M. D. Pietra, 2012 .

Morphologic variations of small cell lung cancer: A histopathologic study of pretreatment and posttreatment specimens in 104 patients

F. Hirsch, M. Sehested, K. Østerlind, 1986, Cancer.

Histopathologic classification of small cell carcinoma of the lung. Comments based on an interobserver examination

F. Hirsch, M. Matthews, R. Yesner, 1982, Cancer.

Staging procedures and prognostic features in small cell anaplastic bronchogenic carcinoma.

F. Hirsch, H. Hansen, P. Dombernowsky, 1978, Seminars in oncology.

The role of the pathologist in the clinical management of lung cancer in the 90's

F. Hirsch, K. Rygaard, F. Hirsch, 1993 .

Biologics: Targets and Therapy Dovepress Clinical and Comparative Utility of Afatinib in Non-small Cell Lung Cancer

F. Hirsch, Manolo D Arcangelo, Manolo D Arcangelo, 2022 .

Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis

V. Torri, H. Wakelee, F. Hirsch, 2022, JTO Clinical and Research Reports.

Central Nervous System Metastases in Small Cell Carcinoma of the Lung — A Review

O. Paulson, F. Hirsch, H. Hansen, 1980 .

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Recurrent Genomic Gains in Preinvasive Lesions as a Biomarker of Risk for Lung Cancer

S. Lam, T. Byers, Y. Miller, 2009, PloS one.

Differentiation of adenocarcinoma of the lung and malignant mesothelioma: predictive value and reproducibility of immunoreactive antibodies

F. Hirsch, B. Skov, T. Skov, 1994, Histopathology.

D. Gandara, J. Moon, P. Mack, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Umbrella Test the effect of one or more drugs on one or more single mutations in a variety of cancer types Test the impact of different drugs on different mutations in a single type of cancer Basket

L. Schwartz, R. Yelensky, M. Leblanc, 2015 .

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

L. Schwartz, R. Herbst, F. Hirsch, 2021, JAMA oncology.

EGFR: a prognostic and/or a predictive marker?

F. Hirsch, F. Hirsch, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift.

V. Rusch, G. Scagliotti, W. Travis, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Interobserver variability in histopathologic subtyping and grading of pulmonary adenocarcinoma

A. Gazdar, F. Hirsch, J. Sørensen, 1993, Cancer.

Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (CP) in chemotherapy-naive advanced NSCLC: Correlation of biomarker status and clinical benefit.

F. Hirsch, P. Bunn, W. Franklin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer

T. Mitsudomi, Jihye Kim, C. Rivard, 2018, Molecular Cancer Therapeutics.

Oncotargets and Therapy Dovepress Dovepress Comparison of Erlotinib and Pemetrexed as Second-/ Third-line Treatment for Lung Adenocarcinoma Patients with Asymptomatic Brain Metastases

C. Rivard, S. Ren, Caicun Zhou, 2022 .

C225 anti-epidermal growth factor receptor (EGFR) monoclonal antibody sensitizes human non-small cell lung cancer to both radiation and chemotherapy cytotoxicity in-vitro and in-vivo

F. Hirsch, P. Bunn, W. Franklin, 2001 .

Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

P. Bunn, R. Dziadziuszko, M. Varella-Garcia, 2006, Clinical Cancer Research.

Frequency and significance of epidermal growth factor receptor mutations detected by PCR methods in patients with non-small cell lung cancer.

K. Furukawa, T. Ohira, N. Ikeda, 2019, Oncology letters.

Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review

F. Hirsch, P. Mack, Ananda M. Rodilla, 2023, Vaccines.

Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study

A. Nicholson, I. Petersen, L. Chirieac, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib

Helen X. Chen, F. Hirsch, D. Gandara, 2005 .

Expression of 'small cell carcinoma antigens' in primary small cell lung cancer and metastases: an immunohistochemical study.

F. Hirsch, B. Skov, L. Bobrow, 1991, The British journal of cancer. Supplement.

Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma

Y. Miller, F. Hirsch, P. Bunn, 2015, Cancer Prevention Research.

Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer.

S. Lam, T. Byers, Y. Miller, 2008, American journal of respiratory and critical care medicine.

High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia.

T. Byers, Y. Miller, T. Petty, 2005, Lung cancer.

Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer.

T. Byers, Y. Miller, F. Hirsch, 2004, Cancer Detection and Prevention.

Sputum Cytologic Atypia Predicts Incident Lung Cancer: Defining Latency and Histologic Specificity

T. Byers, Y. Miller, F. Hirsch, 2008, Cancer Epidemiology Biomarkers & Prevention.

Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma

E. Schadt, W. Oh, Rong Chen, 2022, The oncologist.

Lung Cancer: A multidisciplinary Approach to Diagnosis and Management

F. Hirsch, C. Mascaux, M. Wynes, 2010 .

Chapter 29: Classification of Lung Cancer Histology by Gold Nanoparticle Sensors

H. Haick, F. Hirsch, P. Bunn, 2017 .

Classification of lung cancer histology by gold nanoparticle sensors.

Ulrike Tisch, Hossam Haick, Orna Barash, 2012, Nanomedicine : nanotechnology, biology, and medicine.

Sniffing the unique "odor print" of non-small-cell lung cancer with gold nanoparticles.

Hossam Haick, Orna Barash, H. Haick, 2009, Small.

Serum neuron specific enolase (S-NSE) reference interval evaluation by time-resolved immunofluorometry compared with a radioimmunoassay.

F. Hirsch, G. Momsen, N. Carlsen, 1996, Clinica chimica acta; international journal of clinical chemistry.

Potential future consideration for imaging and blood-based biomarkers for precision medicine in lung cancer.

F. Hirsch, F. Kong, M. Machtay, 2017, Translational lung cancer research.

Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.

F. Hirsch, C. Rivard, Hui Yu, 2020, Clinical lung cancer.

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

F. Hirsch, V. Adamo, A. Naing, 2022, Journal of experimental & clinical cancer research : CR.

23 Validation of PD-L1 dynamic expression on extracellular vesicles as a predictor of response to immune-checkpoint inhibitors and survival in non-small cell lung cancer patients

F. Hirsch, V. Adamo, A. Naing, 2021, Journal for ImmunoTherapy of Cancer.

Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

F. Hirsch, K. Kelly, P. Bunn, 2006, Clinical Cancer Research.

Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A.

P. Hegde, I. Wistuba, F. Hirsch, 2015 .

Loss of STING expression is prognostic in non–small cell lung cancer

F. Hirsch, R. Dziadziuszko, Z. Lohinai, 2022, Journal of surgical oncology.

Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

C. Henschke, D. Yankelevitz, J. Minna, 2022, Cancer Cell.

Fibroblast Growth Factor Receptor 1 as a Putative Therapy Target in Colorectal Cancer

G. Kristiansen, W. Weichert, A. Stenzinger, 2013, Digestion.

Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance

M. Kris, G. Sica, I. Wistuba, 2019, Applied immunohistochemistry & molecular morphology : AIMM.

Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.

P. Bunn, N. Peled, M. Ilouze, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeted molecular mechanisms of epoetin alfa.

F. Hirsch, C. Langer, N. Thatcher, 2003, Lung cancer.

The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients.

F. Hirsch, H. Hansen, P. Dombernowsky, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations.

M. Spitz, A. Flahault, I. Wistuba, 2002, International journal of oncology.

The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers.

F. Hirsch, R. Dziadziuszko, D. Camidge, 2009, Clinical lung cancer.

A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer.

F. Hirsch, H. Hansen, P. B. Jensen, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study

M. Socinski, R. Kurek, F. Hirsch, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The prognostic significance of histopathologic subtyping of small cell carcinoma of the lung according to the classification of the world health organization. A study of 375 consecutive patients

F. Hirsch, H. Hansen, K. Østerlind, 1983, Cancer.

Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?

F. Hirsch, K. Kerr, F. Hirsch, 2016, Archives of pathology & laboratory medicine.

Expression patterns and prognostic relevance of subtype‐specific transcription factors in surgically resected small‐cell lung cancer: an international multicenter study

F. Hirsch, H. Popper, Z. Lohinai, 2022, The Journal of pathology.

SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa).

A. Wozniak, D. Gandara, J. Moon, 2012 .

Chromosomal aneusomy in sputum predicts for lung cancer in nested case-control study.

T. Byers, Y. Miller, W. Franklin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer

T. Ohira, Koichi Yoshida, N. Ikeda, 2013, Cellular Oncology.

Fluorescence in situ hybridization (FISH) subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in NSCLC

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2007 .

B3-04: Gefitinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study

F. Hirsch, E. Duffield, A. Armour, 2007 .

Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341)

J. Crowley, A. Wozniak, D. Gandara, 2007 .

FASTACT-2: but don't act too fast.

F. Hirsch, D. Gandara, F. Hirsch, 2013, The Lancet. Oncology.

Case Presentation Alk Fusions Are Also Associated with Younger Age Next-generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib- Sensitive Alk Rearrangement in a Patient with Metastatic Non–small-cell Lung Cancer

P. Stephens, M. Cronin, F. Hirsch, 2012 .

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

E. Berns, A. Jimeno, D. Lambrechts, 2015, Targeted Oncology.

Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities.

F. Hirsch, V. Miller, David H. Johnson, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus on medical treatment of non-small cell lung cancer.

Christina J. Herold, C. Gridelli, F. Hirsch, 2002, Lung cancer.

Epidermal Growth Factor Receptor Messenger RNAExpression , Gene Dosage , and Gefitinib Sensitivity in Non ^ Small Cell Lung Cancer

F. Cappuzzo, F. Hirsch, P. Bunn, 2006 .

Lung cancer chemoprevention - focus on surrogate markers

F. Hirsch, R. Dziadziuszko, J. Jassem, 2005 .

PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.

F. Hirsch, Å. Helland, O. Brustugun, 2017, Lung cancer.

Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer

S. Ramalingam, H. Borghaei, M. Wynes, 2017, Clinical lung cancer.

Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?

F. Hirsch, P. Bunn, D. Aisner, 2014, Clinical Cancer Research.

Bronchial Epithelial Ki-67 Index Is Related to Histology, Smoking, and Gender, but Not Lung Cancer or Chronic Obstructive Pulmonary Disease

T. Byers, Y. Miller, F. Hirsch, 2007, Cancer Epidemiology Biomarkers & Prevention.

Progress in research on screening and genetics in lung cancer.

P. Bunn, F. Hirsch, 2014, The Lancet. Respiratory medicine.

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.

L. Schwartz, M. Leblanc, R. Herbst, 2020, The Lancet. Oncology.

Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.

F. Hirsch, K. Kelly, A. Wozniak, 2013, Clinical lung cancer.

Antimicrotubule-Platinum Therapy in NSCLS by Histologic Subtypes 628-Introduction

F. Hirsch, A. Wozniak, D. Gandara, 2022 .

Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung

A. Nicholson, A. Borczuk, A. Warth, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy‐Naive Isogenic Lung Cancer Lesions with EGFR Mutation

F. Hirsch, T. Mitsudomi, C. Rivard, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Forty Years of the International Association for Study of Lung Cancer Pathology Committee

A. Nicholson, W. Travis, F. Hirsch, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

International Association for the Study of Lung Cancer (IASLC): celebrating 40 years with scientific and educational achievements!

F. Hirsch, F. Hirsch, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma.

F. Hirsch, D. Gandara, W. Franklin, 2013, Clinical lung cancer.

Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.

F. Hirsch, Keunchil Park, D. Gandara, 2021, Clinical lung cancer.

3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes

P. Hegde, I. Wistuba, S. Gettinger, 2015 .

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials Lung Cancer Coronavirus Disease Clinical

G. Scagliotti, H. Wakelee, T. Mitsudomi, 2022 .

Lung cancer. Introduction.

G. Giaccone, F. Hirsch, P. Bunn, 2003, Lung cancer.